Inhibikase Therapeutics soars as FDA lifts hold on Parkinson's drug trial

Inhibikase Therapeutics

25/01/2023 15:23

** Shares of Inhibikase Therapeutics Inc  IKT.O  rise 14.3%
to $1.03
    ** Drug developer says FDA has lifted the clinical hold on
its lead drug candidate, IkT-148009, which is being developed
for the treatment of Parkinson's disease 
    ** Co expects to restart drug trial by the end of Q1 2023 
    ** FDA lifted the hold based on agreement with co regarding
eye testing and monitoring as part of the trial and modifying
the investigator brochure to remove safety-related data - IKT 
    ** Including session's move, stock down ~23% in past 12
months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))